Delayed vascular changes after antiangiogenic therapy with antivascular endothelial growth factor antibodies in human glioma xenografts in nude mice

被引:17
作者
Bernsen, HJJA
Rijken, PFJW
Peters, JPW
Bakker, H
van der Kogel, AJ
机构
[1] Univ Nijmegen, Inst Radiotherapy, NL-6525 GA Nijmegen, Netherlands
[2] Univ Nijmegen, Dept Pharmacol, NL-6525 GA Nijmegen, Netherlands
[3] Canisius Wilhelmina Hosp, Dept Neurol, Nijmegen, Netherlands
关键词
antiangiogenesis; antivascular endothelial growth factor antibody; glioma; tumor vascularity;
D O I
10.1097/00006123-199809000-00094
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
OBJECTIVE: The purpose of this study was to examine the delayed effects of antivascular endothelial growth factor treatment on tumor growth and vascularity in a subcutaneous mouse tumor model of human glioblastoma. METHODS: Antivascular endothelial growth factor antibody treatment was administered for a period of 6 weeks, to suppress tumor growth. To detect late vascular effects, tumor vascular parameters for treated tumors and control tumors were analyzed 4 weeks thereafter. By that time, tumors had grown to adequate sizes (diameter, 8-10 mm) for comparison with untreated control tumors. Vascular parameters were quantified by using an image-analysis system. RESULTS: Vascular density was significantly lower in antivascular endothelial growth factor antibody-treated tumors, compared with control tumors of similar size. The vascular architecture of treated tumors was also distinctly different, compared with control tumors, showing larger but sparser vessel structures. CONCLUSION: These findings suggest that antiangiogenic therapy may have a prolonged effect on the vascular architecture of certain tumors, resulting in enduring changes in the tumor vessels. Because tumor vasculature plays an important role in the sensitivity to various treatment modalities, these changes are likely to influence the responses of these tumors to further therapy.
引用
收藏
页码:570 / 575
页数:6
相关论文
共 30 条
[1]  
ASANO M, 1995, CANCER RES, V55, P5296
[2]   ANGIOGENESIS INHIBITION - A REVIEW [J].
AUERBACH, W ;
AUERBACH, R .
PHARMACOLOGY & THERAPEUTICS, 1994, 63 (03) :265-311
[3]   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].
Boehm, T ;
Folkman, J ;
Browder, T ;
OReilly, MS .
NATURE, 1997, 390 (6658) :404-407
[4]  
Borgstrom P, 1996, CANCER RES, V56, P4032
[5]  
Devineni D, 1996, CANCER RES, V56, P1983
[6]   CONTROLLING THE VASCULATURE - ANGIOGENESIS, ANTI-ANGIOGENESIS AND VASCULAR TARGETING OF GENE-THERAPY [J].
FAN, TPD ;
JAGGAR, R ;
BICKNELL, R .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (02) :57-66
[7]   MOLECULAR AND BIOLOGICAL PROPERTIES OF THE VASCULAR ENDOTHELIAL GROWTH-FACTOR FAMILY OF PROTEINS [J].
FERRARA, N ;
HOUCK, K ;
JAKEMAN, L ;
LEUNG, DW .
ENDOCRINE REVIEWS, 1992, 13 (01) :18-32
[8]   Seminars in medicine of the Beth Israel Hospital, Boston - Clinical applications of research on angiogenesis [J].
Folkman, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (26) :1757-1763
[9]  
FOLKMAN J, 1991, J CELL BIOCHEM, V47, P199
[10]  
Gulledge CJ, 1996, ANTICANCER RES, V16, P741